Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for prevention of chemotherapy-induced neutropenia in pediatric tumors
ChiCTR2000038246Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Safety of PEG-rhG-CSF in preventing neutropenia after chemotherapy in pediatric tumor patients and Effectiveness of PEG-rhG-CSF in preventing neutropenia after chemotherapy in pediatric tumor patients. Started Oct 2020; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2000038246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038246.